Intravesical Gemcitabine and Docetaxel

Phase 2Small molecule

MMichael A. O'Donnell

Intravesical Gemcitabine and Docetaxel is one of 2 small molecule programs targeting NMIBC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NMIBCNot yet recruiting

NMIBCPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in NMIBC

#DrugCompanyPhaseTrials

Intravesical Gemcitabine and Docetaxel

MMichael A. O'Donnell

Phase 2

1 2

SHR-1501

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2033

Phase 2Not yet recruiting

NMIBC

NCT07322263

Clinical

Trials by Indication[1]

NMIBC1 trial

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Not yet recruiting·MMichael A. O'Donnell·Phase 2·NCT07322263·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravesical Gemcitabine and Docetaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravesical Gemcitabine and Docetaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravesical Gemcitabine and Docetaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Michael A. O'Donnell company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMichael A. O'Donnell

Intravesical Gemcitabine and Docetaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2033

Trials by Indication[1]

NMIBC1 trial

References

Drug Info

Quick Facts

Related News